Mawer Investment Management Ltd. Acquires 10,889 Shares of ResMed Inc. (NYSE:RMD)

Mawer Investment Management Ltd. boosted its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 14.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 87,443 shares of the medical equipment provider's stock after purchasing an additional 10,889 shares during the quarter. Mawer Investment Management Ltd. owned about 0.06% of ResMed worth $19,997,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. True Wealth Design LLC increased its position in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 110 shares in the last quarter. OFI Invest Asset Management bought a new stake in ResMed during the 4th quarter worth approximately $39,000. BankPlus Trust Department purchased a new position in shares of ResMed during the fourth quarter valued at approximately $44,000. Rosenberg Matthew Hamilton purchased a new stake in shares of ResMed in the fourth quarter valued at about $54,000. Finally, SBI Securities Co. Ltd. purchased a new position in ResMed in the fourth quarter worth $67,000. Institutional investors own 54.98% of the company's stock.

ResMed Price Performance

Shares of RMD traded down $1.71 during trading hours on Tuesday, reaching $222.14. 766,886 shares of the company's stock traded hands, compared to its average volume of 1,000,387. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The firm's 50 day simple moving average is $233.37 and its 200-day simple moving average is $237.83. The stock has a market cap of $32.62 billion, a PE ratio of 26.23, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74. ResMed Inc. has a 12 month low of $172.19 and a 12 month high of $263.05.

Remove Ads

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Equities analysts expect that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were given a dividend of $0.53 per share. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the sale, the chief executive officer now directly owns 455,472 shares in the company, valued at $107,842,105.44. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kaushik Ghoshal sold 9,745 shares of ResMed stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,327,289.75. This represents a 50.05 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,940 shares of company stock valued at $9,164,385. Corporate insiders own 0.71% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. KeyCorp boosted their target price on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, March 25th. Morgan Stanley initiated coverage on ResMed in a research note on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 price objective on the stock. Finally, Needham & Company LLC restated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, ResMed has a consensus rating of "Moderate Buy" and a consensus target price of $249.73.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.